Overview
Adam Laponis, Chief Financial Officer of Twist Bioscience Corp (NASDAQ:TWST), executed a sale of 2,597 shares of common stock on April 9, 2026. The transaction was priced at $49.889 per share and totaled $129561. At the time of the sale, shares were trading at $50.38, a level approaching the companys 52-week high of $57.88 after a 59% rise over the past six months.
Ownership and stated purpose of the sale
Following the disposition, Laponis directly holds 125694 shares of Twist Bioscience. Company filings indicate the sale was carried out to cover tax withholding obligations associated with the vesting of restricted stock units, consistent with Twist Biosciences equity incentive plans.
Valuation and third-party analysis
According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate and is listed among companies deemed most overvalued. InvestingPro additionally provides nine exclusive tips for TWST, which include guidance on the companys profitability outlook and financial health.
Recent corporate developments
Twist Bioscience disclosed first-quarter results for fiscal year 2026 showing revenue of $103.7 million, beating analysts forecasts by 2.96%. The company recorded earnings per share of -$0.50, which fell short of the consensus estimate of -$0.43. Separately, Twist announced a licensing agreement with Invenra Inc. for the B-Body bispecific antibody platform, under which Twist will serve as a co-exclusive provider of that technology to bolster its antibody discovery services.
Shareholder actions
At the companys 2026 Annual Meeting, shareholders approved director elections and executive compensation proposals. Approximately 91.81% of outstanding shares eligible to vote were represented at the meeting, reflecting a high level of shareholder participation in the corporate governance decisions.
Key takeaways
- Insider sale of 2,597 shares by the CFO for $129561 was executed to satisfy RSU-related tax withholding obligations.
- Twist reported Q1 fiscal 2026 revenue of $103.7 million, above forecasts, but posted EPS of -$0.50, below estimates.
- The company expanded its discovery services through a licensing agreement with Invenra for the B-Body bispecific antibody platform.
Risks and uncertainties
- Valuation concern: InvestingPro classifies the stock as overvalued relative to its Fair Value estimate, which may affect investor perception of equity markets exposure to the company.
- Profitability uncertainty: Reported EPS of -$0.50 missed expectations of -$0.43, indicating ongoing challenges in achieving anticipated earnings milestones.
- Equity plan impacts: Ongoing vesting of restricted stock units and the related tax-withholding sales could influence share supply dynamics.
Contextual note
These developments - insider selling to meet tax obligations, mixed quarterly results, the new licensing arrangement, and strong shareholder turnout at the annual meeting - together reflect a company managing operational initiatives while navigating market valuation and profitability scrutiny.